Author: Tevogen Bio Inc

Posted Date:

April 27, 2026

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Bio Inc

April 27, 2026
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Bio Inc

March 26, 2026
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen Bio Inc

March 25, 2026
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Tevogen Bio Inc

March 18, 2026
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen Bio Inc

March 13, 2026
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Tevogen Bio Inc

March 13, 2026
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Tevogen Bio Inc

March 11, 2026
Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Tevogen Bio Inc

March 9, 2026
Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Bio Inc

March 6, 2026
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Tevogen Bio Inc

March 5, 2026